THER-33. TOCILIZUMAB AS A POTENTIAL NOVEL THERAPY IN PATIENTS DIAGNOSED WITH ADAMANTINOMATOUS CRANIOPHARYNGIOMA

Adamantinomatous craniopharyngioma (ACP) makes up between 6–8% of pediatric brain tumors and is the most common pediatric tumor arising in the sellar/suprasellar region of the brain. The 10-year survival for patients diagnosed with craniopharyngioma ranges between 64–92%, but given complicating fact...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Grob, Sydney, Donson, Andrew, Prince, Eric, Vijmasi, Trinka, Foreman, Nicholas, Dahl, Nathan, Vibhakar, Rajeev, Mirsky, David, Hankinson, Todd, Levy, Jean Mulcahy
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Translational Therapeutics
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477345/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz036.237
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki